SLNSW-Safety and pharmacokinetics of the antisense olig...-TN_cdi_proquest_journals_1403473642

Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Full title: Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

Author/creator: Erba, Harry P., Sayar, Hamid, Juckett, Mark, Lahn, Michael, Andre, Valerie, Callies, Sophie, Schmidt, Shelly, Kadam, Sunil, Brandt, John T., Van Bockstaele, Dirk, Andreeff, Michael.

Call Numbers:

Record Identifier: TN_cdi_proquest_journals_1403473642

Language: English

Formats: Articles

Publishers: Boston: Springer US

Permalink: https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1403473642

Articles

Articles

Export this record

Export selected records

  • Export to excel
  • Permalink

    • Export record to excel

    File type to download

    Beta version

    Record title

    Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

    Record identifier

    TN_cdi_proquest_journals_1403473642

    Record permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1403473642

    Share

    Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

    ACCESS
    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1403473642

    Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

    Full title

    Safety and pharmacokinetics of the antisense oligonucleotide (ASO) LY2181308 as a single-agent or in combination with idarubicin and cytarabine in patients with refractory or relapsed acute myeloid leukemia (AML)

    Author / Creator

    Erba, Harry P. ; Sayar, Hamid ; Juckett, Mark ; Lahn, Michael ; Andre, Valerie ; Callies, Sophie ; Schmidt, Shelly ; Kadam, Sunil ; Brandt, John T. ; Van Bockstaele, Dirk ; Andreeff, Michael

    Publisher

    Boston: Springer US

    Journal title

    Investigational new drugs, 2013, Vol.31 (4), p.1023-1034

    Record Identifier

    TN_cdi_proquest_journals_1403473642

    Language

    English

    Formats

    Articles

    Publication information

    Publisher

    Subjects

    Subjects and topics

    acute myeloid leukemia Antineoplastic agents Antineoplastic Agents - adverse effects Antineoplastic Agents - blood Antineoplastic Agents - pharmacokinetics Antineoplastic Agents - therapeutic use Antineoplastic Combined Chemotherapy Protocols - adverse effects Antineoplastic Combined Chemotherapy Protocols - blood Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Antineoplastic Combined Chemotherapy Protocols - therapeutic use antisense Apoptosis Biological and medical sciences Bone marrow Cancer therapies Cell cycle Chemotherapy Clinical trials Complications and side effects Cytarabine Cytarabine - adverse effects Cytarabine - blood Cytarabine - pharmacokinetics Cytarabine - therapeutic use Demography Dosage and administration Drug dosages Drug therapy Female Gene expression General aspects Hematologic and hematopoietic diseases Hematology Humans Idarubicin Idarubicin - adverse effects Idarubicin - blood Idarubicin - pharmacokinetics Idarubicin - therapeutic use Inhibitor of Apoptosis Proteins - metabolism Kinases Leukemia Leukemia, Myeloid, Acute - blood Leukemia, Myeloid, Acute - drug therapy Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Male Medical sciences Medicine Medicine & Public Health Meningitis Middle Aged Oligonucleotides - adverse effects Oligonucleotides - blood Oligonucleotides - pharmacokinetics Oligonucleotides - therapeutic use Oligonucleotides, Antisense - adverse effects Oligonucleotides, Antisense - blood Oligonucleotides, Antisense - pharmacokinetics Oligonucleotides, Antisense - therapeutic use Oncology Pharmaceutical sciences Pharmacokinetics Pharmacology. Drug treatments Pharmacology/Toxicology Phase II Studies Recurrence Remission (Medicine) Studies Thrombocytopenia Treatment Outcome Tumors

    More information

    — SCOPE AND CONTENTS

    Contents

    — ALTERNATIVE TITLES

    Full title

    — AUTHORS, ARTISTS AND CONTRIBUTORS

    Author / Creator

    Identifiers

    — PRIMARY IDENTIFIERS

    Record Identifier

    TN_cdi_proquest_journals_1403473642

    Permalink

    https://collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_1403473642

    — OTHER IDENTIFIERS

    ISSN

    E-ISSN

    DOI

    How to access this item

    Online

    1 item

    How to access?

    Login with a Library card

    Full text available >

    About resource >

    About resource >

    View in old catalogue

    Connecting people and collections